Robert A Belderbos1,2, Paul Baas3, Rossana Berardi4, Robin Cornelissen1,2, Dean A Fennell5, Jan P van Meerbeeck6, Arnaud Scherpereel7, Heleen Vroman1,2, Joachim G J V Aerts1,2. 1. Department of Pulmonary Medicine, Erasmus MC Rotterdam, The Netherlands. 2. Erasmus MC Cancer Institute, Erasmus MC Rotterdam, The Netherlands. 3. Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Clinical Oncology, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy. 5. Cancer Research UK Centre, University of Leicester, UK. 6. Department of Thoracic Oncology, University Hospital Antwerp, Belgium. 7. Centre Hospitalier Régional Universitaire de Lille, France.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. Adjuvant bevacizumab generates an additional 2 months survival benefit. Checkpoint inhibitors (CI) have shown promising clinical effects in only a minority of patients. A possible reason is that MPM patients have low numbers of tumor-infiltrating CD8+ T-cells. Dendritic cell (DC) therapy can induce an immune response and activate tumor-specific CD8+ T-cells. Allogeneic mesothelioma tumor-lysate loaded DC therapy has proven effective in mice and safe and feasible in humans. We have designed a randomized, phase II/III, multicenter, open-label trial to examine the efficacy of DC therapy in humans with histologically proven MPM. METHODS: In this open-label, multicenter, randomized phase II/III trial patients will be randomized to receive either DC therapy plus best supportive care (BSC) or BSC alone according to the discretion of the local investigator after first line chemotherapy treatment. The primary end point will be overall survival. The secondary endpoints will be safety and tolerability, progression-free survival, overall response rate and quality of life. DISCUSSION: This phase II/III trial will determine whether DC therapy in patients with MPM is safe and effective as a maintenance treatment and subsequently might be a new treatment option for MPM.
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. Adjuvant bevacizumab generates an additional 2 months survival benefit. Checkpoint inhibitors (CI) have shown promising clinical effects in only a minority of patients. A possible reason is that MPM patients have low numbers of tumor-infiltrating CD8+ T-cells. Dendritic cell (DC) therapy can induce an immune response and activate tumor-specific CD8+ T-cells. Allogeneic mesothelioma tumor-lysate loaded DC therapy has proven effective in mice and safe and feasible in humans. We have designed a randomized, phase II/III, multicenter, open-label trial to examine the efficacy of DC therapy in humans with histologically proven MPM. METHODS: In this open-label, multicenter, randomized phase II/III trial patients will be randomized to receive either DC therapy plus best supportive care (BSC) or BSC alone according to the discretion of the local investigator after first line chemotherapy treatment. The primary end point will be overall survival. The secondary endpoints will be safety and tolerability, progression-free survival, overall response rate and quality of life. DISCUSSION: This phase II/III trial will determine whether DC therapy in patients with MPM is safe and effective as a maintenance treatment and subsequently might be a new treatment option for MPM.
Entities:
Keywords:
Dendritic cell-based therapy; clinical trial; immunotherapy; mesothelioma; phase III
Authors: Vanya Delgermaa; Ken Takahashi; Eun-Kee Park; Giang Vinh Le; Toshiyuki Hara; Tom Sorahan Journal: Bull World Health Organ Date: 2011-06-13 Impact factor: 9.408
Authors: A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder Journal: Zhongguo Fei Ai Za Zhi Date: 2010-10
Authors: Joost P J J Hegmans; Annabrita Hemmes; Joachim G Aerts; Henk C Hoogsteden; Bart N Lambrecht Journal: Am J Respir Crit Care Med Date: 2005-03-11 Impact factor: 21.405
Authors: Joost P Hegmans; Joris D Veltman; Margaretha E Lambers; I Jolanda M de Vries; Carl G Figdor; Rudi W Hendriks; Henk C Hoogsteden; Bart N Lambrecht; Joachim G Aerts Journal: Am J Respir Crit Care Med Date: 2010-02-18 Impact factor: 21.405
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Xabier Mielgo-Rubio; Ana Cardeña Gutiérrez; Verónica Sotelo Peña; Maria Virginia Sánchez Becerra; Andrea María González López; Adriana Rosero; Juan Carlos Trujillo-Reyes; Felipe Couñago Journal: World J Clin Oncol Date: 2022-04-24
Authors: Mario Ghosn; Waseem Cheema; Amy Zhu; Jennifer Livschitz; Majid Maybody; Franz E Boas; Ernesto Santos; DaeHee Kim; Jason A Beattie; Michael Offin; Valerie W Rusch; Marjorie G Zauderer; Prasad S Adusumilli; Stephen B Solomon Journal: Lung Cancer Date: 2022-01-06 Impact factor: 6.081